WGS is a genomic testing and health information services company specializing in diagnostic tests and genomic data analysis. The company provides advanced exome and genome sequencing tests, along with other diagnostic panels, to identify genetic variants and deliver population-specific insights. WGS also collaborates with biopharma companies and leverages data partnerships to generate additional revenue.
- Whole Exome and Whole Genome Tests - Offers advanced sequencing tests to identify genetic variants and provide comprehensive genomic insights, serving as the primary revenue driver for the company.
- Other Panels - Provides various diagnostic panels tailored to specific medical needs, complementing the company's genomic testing offerings.
- Hereditary Cancer Tests - Delivers specialized tests to detect genetic predispositions to hereditary cancers, contributing to the company's diagnostic portfolio.
- Data Information/Other Revenue - Generates revenue through biopharma collaborations and data partnerships, leveraging the company's genomic database for research and development purposes.
You might also like
- Given the unusual sequential decline in Q1 volumes despite a history of rapid growth, can you clarify how much of this is driven by weather disruptions versus seasonal appointment shifts, and what specific strategies you’re implementing to counteract these effects in Q2 and beyond?
- With a notable bump in G&A expenses partly linked to Epic-related costs, can you detail the key cost drivers and explain the measures being taken to ensure operating margins continue to improve over time?
- As you roll out ultraRapid testing with a 2-day turnaround at a premium price, how do you plan to balance the mix with the standard 5-day test and what impact do you expect this will have on overall pricing and gross margins?
- Regarding the acquisition of Fabric Genomics, can you elaborate on how you intend to integrate its high-margin, recurring revenue model without significantly increasing cash burn, and what milestones will determine its success into 2026?
- Your efforts to reduce denial rates and improve reimbursement have seen only modest progress so far; can you provide more detailed plans and timelines regarding how initiatives like Epic Aura will drive these improvements, and what you define as reaching near-optimal reimbursement levels?
Research analysts who have asked questions during GeneDx Holdings earnings calls.
Brandon Couillard
Wells Fargo & Company
5 questions for WGS
Daniel Brennan
TD Cowen
5 questions for WGS
Mark Massaro
BTIG, LLC
5 questions for WGS
William Bonello
Craig-Hallum Capital Group
5 questions for WGS
Tycho Peterson
Jefferies
3 questions for WGS
David Westenberg
Piper Sandler
2 questions for WGS
Matthew Stanton
Jefferies
2 questions for WGS
Matthew Sykes
Goldman Sachs Group Inc.
2 questions for WGS
Subbu Nambi
Guggenheim Securities
2 questions for WGS
Matt Sykes
Goldman Sachs Group, Inc.
1 question for WGS
Competitors mentioned in the company's latest 10K filing.
| Company | Description |
|---|---|
This company is one of the suppliers for GeneDx Holdings Corp. and also competes in the market for genetic information, offering integrated genetic tools and services for health and wellness. | |
Baylor Genetics | This company is listed as a principal competitor in the genetic testing market, providing molecular genetic testing and consulting services. |
This company is identified as a competitor in the genetic testing space, offering services that overlap with GeneDx's offerings. | |
Rady Children’s Hospital | This institution competes in the genetic testing market, particularly in pediatric and rare disease diagnostics. |
This company is noted as a competitor in the genetic testing industry, providing similar services to GeneDx Holdings Corp.. |
| Customer | Relationship | Segment | Details |
|---|---|---|---|
Payor A | Managed care insurance payor | All | 2024 Revenue: $67.21M (22% of $305.5M) ; 2024 A/R: $4.86M (13% of $37.426M). 2023 Revenue: $36.47M (18% of $202.6M) ; 2023 A/R: <10%. |
Payor B | Managed care insurance payor | All | 2024 Revenue: $97.76M (32% of $305.5M) ; 2024 A/R: $4.12M (11% of $37.426M). 2023 Revenue: $56.73M (28% of $202.6M) ; 2023 A/R: $3.24M (10% of $32.371M). |
Recent press releases and 8-K filings for WGS.
- GeneDx reported over $100 million in revenue for the second quarter, driven by strong volume growth, with 75% from existing customers and 25% from new customers, alongside improved revenue cycle management.
- The company maintains an 80% market share among clinical and medical geneticists and is expanding its focus to pediatric specialists, achieving 14% penetration in patients seeing pediatric neurologists.
- GeneDx's competitive advantage is its extensive data asset, comprising over 850,000 rare disease-enriched exomes and genomes and more than 7 million phenotypic data points.
- The company enjoys wide commercial insurance coverage, with 80% of American lives covered, and 35 states now provide coverage for exome testing in the outpatient setting.
- Future growth initiatives include targeting the NICU market, estimated at 250,000 tests annually, and the general pediatrician market, leveraging recently updated AAP guidelines to drive adoption.
- GeneDx achieved a major milestone in Q2 2025, delivering over $100 million in revenue for the first time, with total revenue reaching $102.7 million, a 49% increase year-over-year. The company reported $15 million in adjusted net income, marking its fourth consecutive quarter of profitability.
- Exome and Genome revenue was a record high of $85.9 million, up 69% from the same quarter last year, with 23,102 tests reported, a 28% increase year-over-year. The average reimbursement rate for Exome and Genome tests was over $3,700 per test.
- For the full year 2025, GeneDx raised its total revenue guidance to between $400 million and $415 million and its Exome and Genome revenue growth guidance to 48-52%. The company reaffirmed its expectation for at least 30% Exome and Genome volume growth and to remain profitable each quarter on an adjusted net income basis.
- Growth is expected to be driven by the core customer base, new indications like cerebral palsy, the NICU market (a billion-dollar opportunity), pediatric immunologists, and the general pediatrics market (a $2.5 billion opportunity). As of June 30, 2025, cash, cash equivalents, and marketable securities totaled $135.5 million.
- GeneDx highlighted its differentiated diagnostic approach, leveraging a unique data asset of over 800,000 exomes and genomes and more than 6.1 million phenotypic data points to deliver faster, more conclusive diagnoses for rare diseases.
- The company reported a strong market share in the expert geneticist segment (about 80%) and outlined growth opportunities in pediatric neurology and the NICU space, including a new ultra-rapid 48-hour test turnaround.
- Emphasis was placed on driving conversion from legacy multi-gene panels to whole exome/genome testing to improve unit economics, reduce cost per test, and support future expansion into both pediatric and adult markets.
- Focused on rare disease diagnostics, GeneDx is expanding its exome and genome testing to provide earlier diagnoses for children and improve clinical outcomes.
- Expanding test indications, the company is adding tests for cerebral palsy and immune deficiency disorders and targeting NICU opportunities, with pilot programs initiated to address the significant testing gap in level three and four NICUs.
- Path to profitability is in progress, with a positive adjusted EBITDA reported in Q3 2024, alongside efforts to reduce denial rates and improve gross margins through meticulous cost management and payer engagement.
- Strategic M&A move, the acquisition of Fabric’s AI-driven interpretation platform aims to enhance international market access and drive further efficiencies in the diagnostic process.
- GeneDx announced its plan to acquire Fabric Genomics to expand its decentralized, AI-powered genomic testing platform, which will enhance genomic insights and accelerate testing capabilities in NICUs and newborn screening.
- The transaction involves an upfront payment of $33 million with total potential consideration up to $51 million, and is expected to close in the second quarter of 2025, positioning the company for growth in global genomic markets.